Premier Anti-Aging Co., Ltd. (JP:4934)
:4934
4934 Stock Chart & Stats
¥702.00
-¥12.00(-1.43%)
At close: 4:00 PM EST
¥702.00
-¥12.00(-1.43%)
Day’s Range― - ―
52-Week Range¥593.00 - ¥979.00
Previous CloseN/A
Volume17.40K
Average Volume (3M)11.01K
Market Cap
¥5.35B
Enterprise Value¥1.43B
Total Cash (Recent Filing)¥4.66B
Total Debt (Recent Filing)¥1.11B
Price to Earnings (P/E)42.4
Beta1.03
Next Earnings
Jun 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.26
Shares Outstanding8,720,534
10 Day Avg. Volume8,960
30 Day Avg. Volume11,006
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)1.14
Price to Sales (P/S)0.47
P/FCF Ratio5.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)49.3
Revenue Forecast (FY)¥15.00B
Bulls Say, Bears Say
Bulls Say
High Gross Profit MarginA 76.65% gross profit margin indicates significant product-level pricing power and low direct costs. That durable margin buffer helps absorb SG&A and supports investment in R&D and marketing, improving chances to restore operating leverage if revenue trends stabilize.
Conservative Leverage And Healthy EquityA debt-to-equity ratio of 0.17 and a healthy equity base give the company financial flexibility to fund initiatives or weather downturns without material refinancing risk. Moderate ROE (7.13%) shows reasonable shareholder returns while preserving balance-sheet optionality.
Strong Free Cash Flow ConversionNear-parity free cash flow to net income (0.98) and a notable improvement from a prior negative base indicate the company is effectively converting earnings into cash. Sustained FCF conversion supports capex, deleveraging, or strategic investments over the medium term.
Bears Say
Declining Revenue TrendMultiyear revenue declines (Fundamentals growth -17.9% and a recent-year drop of -7.23%) point to persistent demand weakness or competitive erosion. A shrinking top line reduces operating leverage, limits reinvestment capacity, and makes margin recovery and scale economics harder to achieve.
Low Net And Operating MarginsA net profit margin of only 2.91% and weak EBIT/EBITDA indicate limited profitability after operating costs. Low margins constrain the firm's ability to self-fund growth, leave limited room for price or cost shocks, and require structural improvements to sustainably raise returns to shareholders.
Weak Operating Cash Flow ConversionOperating cash flow equals only about 49% of net income, suggesting earnings convert to cash less efficiently. This raises concerns about earnings quality and working-capital sensitivity, potentially limiting reliable internal funding for capex, dividends, or debt servicing in adverse periods.
Premier Anti-Aging Co., Ltd. News
4934 FAQ
What was Premier Anti-Aging Co., Ltd.’s price range in the past 12 months?
Premier Anti-Aging Co., Ltd. lowest stock price was ¥593.00 and its highest was ¥979.00 in the past 12 months.
What is Premier Anti-Aging Co., Ltd.’s market cap?
Premier Anti-Aging Co., Ltd.’s market cap is ¥5.35B.
When is Premier Anti-Aging Co., Ltd.’s upcoming earnings report date?
Premier Anti-Aging Co., Ltd.’s upcoming earnings report date is Jun 15, 2026 which is in 80 days.
How were Premier Anti-Aging Co., Ltd.’s earnings last quarter?
Premier Anti-Aging Co., Ltd. released its earnings results on Mar 12, 2026. The company reported ¥4.26 earnings per share for the quarter, beating the consensus estimate of N/A by ¥4.26.
Is Premier Anti-Aging Co., Ltd. overvalued?
According to Wall Street analysts Premier Anti-Aging Co., Ltd.’s price is currently Overvalued.
Does Premier Anti-Aging Co., Ltd. pay dividends?
Premier Anti-Aging Co., Ltd. does not currently pay dividends.
What is Premier Anti-Aging Co., Ltd.’s EPS estimate?
Premier Anti-Aging Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Premier Anti-Aging Co., Ltd. have?
Premier Anti-Aging Co., Ltd. has 8,720,534 shares outstanding.
What happened to Premier Anti-Aging Co., Ltd.’s price movement after its last earnings report?
Premier Anti-Aging Co., Ltd. reported an EPS of ¥4.26 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.688%.
Which hedge fund is a major shareholder of Premier Anti-Aging Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4934
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Premier Anti-Aging Co., Ltd.
Premier Anti-Aging Co., Ltd. engages in the planning, development, import/export, mail order, wholesale, and retail business of cosmetics and health foods. The company offers its cosmetic products under the DUO and CANADEL brands. It is also involved on the information provision and consulting services related to anti-aging, beauty, and health; research on management and beauty of beauty clinics, etc.; and marketing research and collection and analysis of various information. The company was founded in 2009 and is headquartered in Tokyo, Japan.
Technical Analysis
Ivy Cosmetics Corporation
―
HABA Laboratories, Inc.
―
C'BON COSMETICS Co., Ltd.
―
I-ne CO., LTD.
―
AXXZIA, Inc.
―